Anti-spike protein IgG antibody responses up to 3 months after the third dose of the BNT162b2 mRNA vaccine in medical care workers

IF 1.8 Q2 MEDICINE, GENERAL & INTERNAL

Journal of General and Family Medicine Pub Date : 2024-03-26 DOI:10.1002/jgf2.688

Harukazu Hirano MD

{"title":"Anti-spike protein IgG antibody responses up to 3 months after the third dose of the BNT162b2 mRNA vaccine in medical care workers","authors":"Harukazu Hirano MD","doi":"10.1002/jgf2.688","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>This study aimed to assess the changes in anti-spike protein IgG antibody titer over time following mRNA vaccination (BNT162b2) against severe acute respiratory syndrome coronavirus 2.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We monitored IgG levels in 23 medical care workers (MCWs) for up to 3 months after administering the third dose of BNT162b2. Blood samples were periodically collected from all participants.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Following the third dose, the median antibody titer increased to 252 and 327% compared with antibody levels at 1 and 3 months after the second dose, respectively. Additionally, compared with 1 month after the second dose, the median antibody titer decreased to 30.2 and 9.8% at 3 and 6 months, respectively, and to 39.1% at 3 months, compared with 1 month after the third dose.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Antibody levels declined quickly after the second dose but declined more slowly after the third dose, showing a booster effect. This study provides insights into the immunogenicity of booster doses and time intervals for booster vaccination strategies.</p>\n </section>\n </div>","PeriodicalId":51861,"journal":{"name":"Journal of General and Family Medicine","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgf2.688","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of General and Family Medicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jgf2.688","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

This study aimed to assess the changes in anti-spike protein IgG antibody titer over time following mRNA vaccination (BNT162b2) against severe acute respiratory syndrome coronavirus 2.

Methods

We monitored IgG levels in 23 medical care workers (MCWs) for up to 3 months after administering the third dose of BNT162b2. Blood samples were periodically collected from all participants.

Results

Following the third dose, the median antibody titer increased to 252 and 327% compared with antibody levels at 1 and 3 months after the second dose, respectively. Additionally, compared with 1 month after the second dose, the median antibody titer decreased to 30.2 and 9.8% at 3 and 6 months, respectively, and to 39.1% at 3 months, compared with 1 month after the third dose.

Conclusion

Antibody levels declined quickly after the second dose but declined more slowly after the third dose, showing a booster effect. This study provides insights into the immunogenicity of booster doses and time intervals for booster vaccination strategies.

Abstract Image

查看原文本刊更多论文

医护人员接种第三剂 BNT162b2 mRNA 疫苗 3 个月后的抗尖峰蛋白 IgG 抗体反应

本研究旨在评估接种 mRNA 疫苗（BNT162b2）预防严重急性呼吸系统综合征冠状病毒 2 后抗尖峰蛋白 IgG 抗体滴度随时间的变化情况。我们对 23 名医护人员在注射第三剂 BNT162b2 后长达 3 个月的 IgG 水平进行了监测，并定期采集所有参与者的血样。此外，与第二剂后1个月相比，抗体滴度中位数在3个月和6个月时分别降至30.2%和9.8%，在3个月时降至39.1%。这项研究为加强剂量的免疫原性和加强接种策略的时间间隔提供了启示。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊